Updates are available Correction dated 2023-01-06
Click to view Correction: https://doi.org/10.1007/s00401-022-02536-y
-
Authors
Perneel, Jolien
Neumann, Manuela
Heeman, Bavo
Cheung, Simon
Van den Broeck, Marleen
Wynants, Sarah
Baker, Matt
Vicente, Cristina T.
Faura, Júlia
Rademakers, Rosa
Mackenzie, Ian R. A. https://orcid.org/0000-0003-3875-2972
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (74580)
National Institutes of Health (UAG063911)
National Institutes of Health (UG3 NS103870)
Universiteit Antwerpen
Vlaams Instituut voor Biotechnologie
Flanders Research Foundation
Association for Frontotemporal Degeneration
- License Information
-
More Information
Article History
Received: 24 October 2022
Revised: 21 November 2022
Accepted: 9 December 2022
First Online: 17 December 2022
Change Date: 6 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00401-022-02536-y
Declarations
:
: Dr. Rademakers is a member of the Scientific Advisory Board of Arkuda Therapeutics and receives invention royalties from a patent related to progranulin. Dr. Mackenzie is a member of the Scientific Advisory Board of Prevail Therapeutics and receives invention royalties from a patent related to progranulin.
